News and Views
Nature Medicine 14, 494 - 495 (2008)
doi:10.1038/nm0508-494
Bedside to bench: Interfering with leukemic stem cells
Daniela S Krause1 & Richard A Van Etten1
- Daniela S. Krause is at the Massachusetts General Hospital, Department of Pathology, 55 Fruit Street, Boston, Massachusetts 02114, USA.
-
Richard A. Van Etten is at the Molecular Oncology Research Institute and Division of Hematology/Oncology, Tufts Medical Center, 800 Washington Street, Boston, Massachusetts 02111, USA.
e-mail: rvanetten@tuftsmedicalcenter.org
Abstract
Kinase inhibitors such as imatinib (Gleevec) have improved the outlook for many people with chronic myeloid leukemia and related blood disorders. But such drugs do not target the leukemia stem cell population and may not be curative. Krause and Van Etten discuss several clinical studies that suggest that interferon-
may provide a solution by selectively eliminating leukemic stem cells—although only more basic research will tell us whether this is true and how it may happen.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
IFN-α wakes up sleeping hematopoietic stem cellsNature Medicine News and Views (01 Jun 2009)
Killing two kinase families with one stoneNature Chemical Biology News and Views (01 Nov 2008)
RESEARCH
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in miceLeukemia Original Article
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanismLeukemia Original Article
See all 34 matches for Research
